These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
180 related items for PubMed ID: 8112185
1. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A. Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185 [Abstract] [Full Text] [Related]
3. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C. Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927 [Abstract] [Full Text] [Related]
4. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648 [Abstract] [Full Text] [Related]
5. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025 [Abstract] [Full Text] [Related]
6. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study. Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA. Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729 [Abstract] [Full Text] [Related]
7. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group. Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358 [Abstract] [Full Text] [Related]
9. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Scott LJ, Spencer CM. Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834 [Abstract] [Full Text] [Related]
11. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office]. Fehmann HC. Fortschr Med Orig; 2001 Jul 19; 119 Suppl 2():55-61. PubMed ID: 15704357 [Abstract] [Full Text] [Related]
12. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Pagano G, Marena S, Corgiat-Mansin L, Cravero F, Giorda C, Bozza M, Rossi CM. Diabete Metab; 1995 Jun 19; 21(3):162-7. PubMed ID: 7556806 [Abstract] [Full Text] [Related]
16. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Standl E, Schernthaner G, Rybka J, Hanefeld M, Raptis SA, Naditch L. Diabetes Res Clin Pract; 2001 Mar 19; 51(3):205-13. PubMed ID: 11269893 [Abstract] [Full Text] [Related]
20. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes. Heinz G, Komjati M, Korn A, Waldhäusl W. Eur J Clin Pharmacol; 1989 Mar 19; 37(1):33-6. PubMed ID: 2687007 [Abstract] [Full Text] [Related] Page: [Next] [New Search]